Baidu
map

Nat Commun:甲基化测序捕捉三阴性乳腺癌表观遗传特性

2015-02-05 佚名 生物谷

近日,一篇刊登在国际杂志Nature Communications上的研究报告中,来自澳大利亚悉尼加文医学研究所(Garvan Institute of Medical Research)的科学家们通过将乳腺癌患者机体的乳腺癌甲基化组同健康个体进行比较从而绘制出了一种新型的基因组图谱,其可以帮助揭示DNA如何被甲基化基团进行修饰,即DNA的甲基化过程。 本文研究揭示了乳腺癌细胞主要活检组织中

近日,一篇刊登在国际杂志Nature Communications上的研究报告中,来自澳大利亚悉尼加文医学研究所(Garvan Institute of Medical Research)的科学家们通过将乳腺癌患者机体的乳腺癌甲基化组同健康个体进行比较从而绘制出了一种新型的基因组图谱,其可以帮助揭示DNA如何被甲基化基团进行修饰,即DNA的甲基化过程。

本文研究揭示了乳腺癌细胞主要活检组织中不同的甲基化模式,其可以有效揭示患者的预后情况;三阴性乳腺癌在所有乳腺癌中占到了15%至20%,患该类乳腺癌的患者相比其它乳腺癌患者的复发风险和死亡率都较高;三阴性乳腺癌患者往往分为两类:第一类是不管是否进行治疗患者在3-5年内就会死亡;第二类是平均比非三阴性乳腺癌患者存活时间更长的患者群(在诊断后至少可以存活8年)。

目前并没有可靠的方法来对上述两类三阴性乳腺癌进行区分,而临床医生往往依据肿瘤的尺寸、扩散程度以及淋巴结的渗透性来决定患者应该被分为高风险类还是低风险类中。Susan Clark教授说道,文章中我们对三阴性乳腺癌患者的组织样本和配对的正常样本进行全基因组甲基化捕捉测序,同时进行新一代的测序来确定癌症在DNA甲基化中的特异性改变。

这项研究首次调查了三阴性乳腺癌的甲基化组及其和疾病预后的关联情况,目前在进行该疾病的有效管理上仍然缺乏相关的依据,由于缺少强大的检测诊断工具,很多女性都存在治疗过度的情况。研究者指出,根据肿瘤的表观遗传特性对其进行分类,我们就可以随着时间对选择性的乳腺癌群体进行追踪,及时监测患者对不同疗法的反应情况。

目前研究者Clare Stirzaker及其同事开发出的新型方法可以对归档的组织进行DNA提取来对甲基化组进行测序,从而实现将患者的甲基化模式同其疾病预后相联系起来。开发一种甲基化的测序技术也可以帮助研究者进行更多深入的研究。最后研究者表示,本文研究或为后期开发乳腺癌的新型诊断工具提供一定的帮助和线索。

原始出处

Stirzaker C1, Zotenko E1, Song JZ2, Qu W2, Nair SS1, Locke WJ1, Stone A1, Armstong NJ3, Robinson MD4, Dobrovic A5, Avery-Kiejda KA6, Peters KM7, French JD8, Stein S9, Korbie DJ10, Trau M11, Forbes JF12, Scott RJ13, Brown MA7, Francis GD14, Clark SJ1.Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic value.Nat Commun. 2015 Feb 2

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2086764, encodeId=b5422086e649b, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Jul 03 01:17:00 CST 2015, time=2015-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15927, encodeId=e0a21592e7b, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 14:49:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880488, encodeId=599c1880488e5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Oct 07 14:17:00 CST 2015, time=2015-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047927, encodeId=a3d6204e927eb, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Thu Aug 20 18:17:00 CST 2015, time=2015-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458654, encodeId=08821458654d3, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19820, encryptionId=3ef91982030, topicName=三阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5666112721, createdName=xlysu, createdTime=Sat Feb 07 00:17:00 CST 2015, time=2015-02-07, status=1, ipAttribution=)]
    2015-07-03 liuli5079
  2. [GetPortalCommentsPageByObjectIdResponse(id=2086764, encodeId=b5422086e649b, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Jul 03 01:17:00 CST 2015, time=2015-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15927, encodeId=e0a21592e7b, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 14:49:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880488, encodeId=599c1880488e5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Oct 07 14:17:00 CST 2015, time=2015-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047927, encodeId=a3d6204e927eb, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Thu Aug 20 18:17:00 CST 2015, time=2015-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458654, encodeId=08821458654d3, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19820, encryptionId=3ef91982030, topicName=三阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5666112721, createdName=xlysu, createdTime=Sat Feb 07 00:17:00 CST 2015, time=2015-02-07, status=1, ipAttribution=)]
    2015-02-16 windmilL1989

    已阅

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2086764, encodeId=b5422086e649b, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Jul 03 01:17:00 CST 2015, time=2015-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15927, encodeId=e0a21592e7b, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 14:49:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880488, encodeId=599c1880488e5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Oct 07 14:17:00 CST 2015, time=2015-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047927, encodeId=a3d6204e927eb, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Thu Aug 20 18:17:00 CST 2015, time=2015-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458654, encodeId=08821458654d3, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19820, encryptionId=3ef91982030, topicName=三阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5666112721, createdName=xlysu, createdTime=Sat Feb 07 00:17:00 CST 2015, time=2015-02-07, status=1, ipAttribution=)]
    2015-10-07 liye789132251
  4. [GetPortalCommentsPageByObjectIdResponse(id=2086764, encodeId=b5422086e649b, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Jul 03 01:17:00 CST 2015, time=2015-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15927, encodeId=e0a21592e7b, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 14:49:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880488, encodeId=599c1880488e5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Oct 07 14:17:00 CST 2015, time=2015-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047927, encodeId=a3d6204e927eb, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Thu Aug 20 18:17:00 CST 2015, time=2015-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458654, encodeId=08821458654d3, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19820, encryptionId=3ef91982030, topicName=三阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5666112721, createdName=xlysu, createdTime=Sat Feb 07 00:17:00 CST 2015, time=2015-02-07, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2086764, encodeId=b5422086e649b, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Jul 03 01:17:00 CST 2015, time=2015-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15927, encodeId=e0a21592e7b, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 14:49:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880488, encodeId=599c1880488e5, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Oct 07 14:17:00 CST 2015, time=2015-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047927, encodeId=a3d6204e927eb, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Thu Aug 20 18:17:00 CST 2015, time=2015-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458654, encodeId=08821458654d3, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19820, encryptionId=3ef91982030, topicName=三阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5666112721, createdName=xlysu, createdTime=Sat Feb 07 00:17:00 CST 2015, time=2015-02-07, status=1, ipAttribution=)]
    2015-02-07 xlysu

相关资讯

Oncogene:揭示攻击癌症干细胞的新策略

来自密歇根大学综合癌症中心和乔治亚摄政大学的研究人员发现,一种叫做SOCS3的蛋白在正常细胞中高水平表达,而在三阴性乳腺癌中则检测不到这种蛋白。他们证实这一蛋白在癌症中降解,导致了细胞中与炎性分子IL6相关的一个反馈回路的关闭开关被阻断。当这一开关无法关闭之时,其促进了癌症干细胞生长。这一研究发现为治疗最具侵袭性的三阴性乳腺癌提供了一个潜在的靶点。相关论文发表在Oncogene杂志上。 研究作者

JCO:西妥昔单抗联合顺铂可改善三阴性乳腺癌患者生存

作为乳腺癌中的一种侵袭性亚型,转移性三阴性乳腺癌(mTNBC)会出现表皮生长因子受体的过量表达。针对这种情况,美国纪念斯隆凯特琳癌症中心的Jose Baselga博士等人进行了一项研究,这项项随机临床II期研究对顺铂联合或部联合西妥昔单抗进行了考察。该研究结果发表于2013年6月3日在线出版的《临床肿瘤学杂志》(Journal of ClinicalOncology)上。 参试患者此前未接受或仅

“联合预测模型”为分类治疗三阴性乳腺癌导航

大会主席邵志敏教授主持第13届全国乳腺癌会议暨第9届上海国际乳腺癌论坛开幕式场景(孙国根摄) 讯 (驻地记者 孙国根) 复旦大学附属肿瘤医院乳腺外科邵志敏教授领衔的科研团队经多年临床实践和研究创建的“联合预测模型”有望破解三阴性乳腺癌等易复发、易转移的乳腺癌“生物学密码”,大幅度提高其治疗效果。这是记者在10月24日在上海举行的第13届全国乳腺癌会议暨第9届上海国际乳腺癌论坛上获

Evid Based Complement Alternat Med:中西医结合治疗三阴性乳腺癌安全有效

Evid Based Complement Alternat Med:中西医结合治疗三阴性乳腺癌安全有效 背景:三阴性乳腺癌(TNBC)是具有高度侵袭性的一种亚型,常发生与年轻女性,容易复发转移,由于缺少荷尔蒙受体和HER-2受体,治疗只能通过化疗。TNBC的侵袭性是通过抑制抑癌基因PTEN表现更强的PI3K通路途径实现的。表皮生长因子受体(EGFR)是ERBB/HER家族跨膜络氨酸激酶受体

SABCS 2014:Pembrolizumab使部分三阴性乳腺癌患者产生持续应答

第37届圣安东尼奥乳腺癌研讨会上的一项1期研究( 摘要号#S1-09.)结果显示,对于具有PD-L1肿瘤的经化疗的转移性,三阴性乳腺癌患者,人源化抗PD-1抗体pembrolizumab可以使其中近20%的患者产生持久应答。“目前没有获准的用于转移性三阴性乳腺癌的靶向治疗,该病患者的中位生存期大约为1年,”芝加哥大学医学助理教授和乳腺肿瘤医学项目的副主任 Rita Nanda博士说。 “

Cancer Res:三阴性乳腺癌研究获进展

《癌症研究》杂志日前在线发表了上海交通大学基础医学院王建华团队的最新研究成果。相关专家认为,该研究为临床上寻找三阴性乳腺癌合适的治疗靶点具有重要意义。 据了解,HIC1是一种肿瘤抑制因子,位于人类第17号染色体短臂。该基因在很多实体肿瘤组织中存在表达沉默的现象。王建华团队从表观遗传学修饰的角度,在阐明HIC1调控前列腺癌发展、转移中的作用机制后,又发现了HIC1的表达沉默只发生在三阴性乳腺癌中。

Baidu
map
Baidu
map
Baidu
map